+

WO2008024490A3 - Formulations pharmaceutiques à usage oral de cannabinoïdes dissuadant les abus et leur procédé d'utilisation - Google Patents

Formulations pharmaceutiques à usage oral de cannabinoïdes dissuadant les abus et leur procédé d'utilisation Download PDF

Info

Publication number
WO2008024490A3
WO2008024490A3 PCT/US2007/018779 US2007018779W WO2008024490A3 WO 2008024490 A3 WO2008024490 A3 WO 2008024490A3 US 2007018779 W US2007018779 W US 2007018779W WO 2008024490 A3 WO2008024490 A3 WO 2008024490A3
Authority
WO
WIPO (PCT)
Prior art keywords
cannabinoids
pharmaceutical formulations
oral pharmaceutical
abuse deterrent
abuse
Prior art date
Application number
PCT/US2007/018779
Other languages
English (en)
Other versions
WO2008024490A2 (fr
Inventor
Najib Babul
Original Assignee
Theraquest Biosciences Inc
Najib Babul
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theraquest Biosciences Inc, Najib Babul filed Critical Theraquest Biosciences Inc
Publication of WO2008024490A2 publication Critical patent/WO2008024490A2/fr
Publication of WO2008024490A3 publication Critical patent/WO2008024490A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques d'agonistes des cannabinoïdes et leur utilisation pour empêcher l'abus d'agonistes des cannabinoïdes et l'abus d'agonistes des opioïdes ou en minimiser le risque. La présente invention concerne également un procédé consistant à empêcher l'abus d'agonistes des cannabinoïdes et l'abus d'agonistes des opioïdes ou en minimiser le risque.
PCT/US2007/018779 2006-08-24 2007-08-24 Formulations pharmaceutiques à usage oral de cannabinoïdes dissuadant les abus et leur procédé d'utilisation WO2008024490A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83968506P 2006-08-24 2006-08-24
US60/839,685 2006-08-24

Publications (2)

Publication Number Publication Date
WO2008024490A2 WO2008024490A2 (fr) 2008-02-28
WO2008024490A3 true WO2008024490A3 (fr) 2008-10-16

Family

ID=39107448

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/018779 WO2008024490A2 (fr) 2006-08-24 2007-08-24 Formulations pharmaceutiques à usage oral de cannabinoïdes dissuadant les abus et leur procédé d'utilisation

Country Status (1)

Country Link
WO (1) WO2008024490A2 (fr)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
US9533938B2 (en) 2007-01-31 2017-01-03 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
LT2368555T (lt) 2007-01-31 2016-09-26 Biosuccess Biotech Company Forbolio esterių kompozicijos ir jų panaudojimo būdai
US11564901B2 (en) 2007-01-31 2023-01-31 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters
US11696908B2 (en) 2007-01-31 2023-07-11 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US10369222B2 (en) 2012-01-18 2019-08-06 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
US9636317B2 (en) 2007-01-31 2017-05-02 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US9974764B2 (en) 2007-01-31 2018-05-22 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
EP2379111B1 (fr) 2008-12-12 2013-03-20 Paladin Labs Inc. Formulations médicamenteuses narcotiques avec un potentiel d'abus réduit
US9125867B2 (en) 2010-02-24 2015-09-08 Invincible Biotechnology Diversion- and/or abuse-resistant compositions and methods for making the same
US9775379B2 (en) 2010-12-22 2017-10-03 Syqe Medical Ltd. Method and system for drug delivery
JP2014511382A (ja) 2011-02-23 2014-05-15 コエルルウス リミテッド フルマゼニル錯体、それを含む組成物、およびその使用
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
US10099996B2 (en) 2012-01-18 2018-10-16 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
US9550722B2 (en) 2012-01-18 2017-01-24 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbal esters for the treatment of stroke
US20140179727A1 (en) 2012-12-14 2014-06-26 Trevi Therapeutics, Inc. Methods for treating pruritus
US8987289B2 (en) 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
US8637538B1 (en) 2012-12-14 2014-01-28 Trevi Therapeutics, Inc. Methods for treatment of pruritis
DK2953934T3 (en) 2013-02-08 2018-05-28 Gen Mills Inc FOODS WITH REDUCED SODIUM CONTENT
ES2610988T3 (es) 2013-10-29 2017-05-04 Echo Pharmaceuticals B.V. Comprimido que contiene cannabidiol, método para su producción y uso de tal comprimido en el tratamiento oral de trastornos psicóticos o de ansiedad
WO2015065180A1 (fr) 2013-10-29 2015-05-07 Echo Pharmaceuticals B.V. Comprimé contenant du delta 9-tétrahydrocannabinol, procédé de fabrication associé et utilisation de ce comprimé pour un traitement oral
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
WO2016001922A1 (fr) 2014-06-30 2016-01-07 Syqe Medical Ltd. Procédés, dispositifs et systèmes utilisables en vue de l'administration pulmonaire d'agents actifs
RU2690401C2 (ru) 2014-06-30 2019-06-03 Сике Медикал Лтд. Способ и устройство для испарения и ингаляции выделенных веществ
IL285111B (en) 2014-06-30 2022-07-01 Syqe Medical Ltd Flow regulating inhaler device
WO2016001925A1 (fr) 2014-06-30 2016-01-07 Syqe Medical Ltd. Cartouche de dose de médicament pour un dispositif d'inhalateur
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
EP3160565B1 (fr) 2014-06-30 2021-08-18 Syqe Medical Ltd. Dispositifs et systèmes pour administration pulmonaire d'agents actifs
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
JP6696994B2 (ja) 2014-12-08 2020-05-20 クレシオ・バイオサイエンシズ・リミテッド 即放性乱用抑止性顆粒剤形
WO2016154032A1 (fr) * 2015-03-20 2016-09-29 Zen Potion, Inc. Préparation de boissons contenant des cannabinoïdes utilisant des récipients comportant des matrices polymères
WO2017118980A1 (fr) 2016-01-06 2017-07-13 Syqe Medical Ltd. Traitement thérapeutique à faible dose
CA3010861A1 (fr) * 2016-01-08 2017-07-13 Colonaryconcepts Llc Administration de cannabinoides par l'intermediaire d'aliments
WO2018000094A1 (fr) 2016-06-29 2018-01-04 CannScience Innovations Inc. Résines de cannabis décarboxylées, leurs utilisations et leurs procédés de fabrication
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
US20180110730A1 (en) * 2016-10-20 2018-04-26 Axim Biotechnologies, Inc. Chewing gum composition comprising cannabinoids and opioid agonists and/or antagonists
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
WO2019171332A1 (fr) * 2018-03-08 2019-09-12 Victoria Link Ltd Traitement de maladies démyélinisantes
CA3091752A1 (fr) 2018-03-08 2019-09-12 Victoria Link Ltd Traitement de maladies demyelinisantes
CA3104795A1 (fr) * 2018-06-28 2020-01-02 Canopy Growth Corporation Compositions et procedes d'agonisation de recepteur cb2
WO2020010166A1 (fr) * 2018-07-02 2020-01-09 Aardvark Therapeutics Inc. Formulations pharmaceutiques orales de composés amers contre l'asthme
US20200022974A1 (en) 2018-07-23 2020-01-23 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness and dyspnea
US20200179271A1 (en) * 2018-12-07 2020-06-11 Opiant Pharmaceuticals, Inc. Compositions and methods for treating acute cannabinoid overdose with a cannabinoid receptor antagonist
US11324707B2 (en) 2019-05-07 2022-05-10 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
GB2584341B (en) * 2019-05-31 2023-03-01 Gw Res Ltd Cannabinoid formulations
AU2020296012A1 (en) 2019-06-18 2022-01-20 Indivior Uk Limited Compositions and methods for treating cannabinoid hyperemesis syndrome with a cannabinoid receptor antagonist
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
EP4045024A4 (fr) 2019-10-14 2023-10-25 Pike Therapeutics, Inc. Administration transdermique de cannabidiol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
EP3808336A1 (fr) 2019-10-16 2021-04-21 ADD Advanced Drug Delivery Technologies, Ltd. Formulations à libération contrôlée des substances actives physiologiques très lipophiles
EP3808341A1 (fr) 2019-10-16 2021-04-21 ADD Advanced Drug Delivery Technologies, Ltd. Formulations à libération contrôlée des substances actives physiologiques très lipophiles
NL2024652B1 (en) * 2020-01-10 2021-09-07 Stabican B V Process for preparing cannabinoid-containing particles
JP2023510341A (ja) 2020-01-10 2023-03-13 トレビ セラピューティクス インコーポレイテッド ナルブフィン投与メソッド
US20230149338A1 (en) * 2020-04-14 2023-05-18 The Regents Of The University Of California Diagnosis and treatment of addiction
AU2021270969A1 (en) 2020-05-11 2022-12-08 Add Advanced Drug Delivery Technologies Ltd. Uses and formulations of cannabinoids
EP4149448A1 (fr) 2020-05-11 2023-03-22 ADD Advanced Drug Delivery Technologies, Ltd. Utilisations et formulations de cannabinoïdes
AU2020447636A1 (en) 2020-05-11 2022-12-08 Add Advanced Drug Delivery Technologies Ltd. Uses and formulations of cannabinoids
US20230201284A1 (en) 2020-05-11 2023-06-29 Add Advanced Drug Delivery Technologies Ltd. Uses and Formulations of Cannabinoids
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
EP4074307A1 (fr) 2021-04-16 2022-10-19 ADD Advanced Drug Delivery Technologies, Ltd. Formulations de cannabinoïdes
WO2022219198A1 (fr) 2021-04-16 2022-10-20 Add Advanced Drug Delivery Technologies Ltd. Formulations de cannabinoïdes
WO2024130236A2 (fr) * 2022-12-16 2024-06-20 University Of Connecticut Compositions analgésiques, leur méthodes de fabrication et leurs utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent

Also Published As

Publication number Publication date
WO2008024490A2 (fr) 2008-02-28

Similar Documents

Publication Publication Date Title
WO2008024490A3 (fr) Formulations pharmaceutiques à usage oral de cannabinoïdes dissuadant les abus et leur procédé d'utilisation
WO2008021394A3 (fr) Formulations pharmaceutiques d'agonistes cannabinoïdes et procédé d'utilisation
WO2008027442A3 (fr) Formulations pharmaceutiques orales anti-abus à base d'opioïdes et procédé d'utilisation
WO2008024408A3 (fr) Formulations pharmaceutiques de cannabinoïdes destinées à être appliquées sur la peau et leur procédé d'utilisation
WO2007087452A3 (fr) Formulations à libération prolongée empêchant l'usage abusif et méthodes d'utilisation de celles-ci
WO2008033351A3 (fr) Formulations multimode de libération prolongée et résistantes à l'abus
WO2008076754A3 (fr) Composés et compositions utilisés comme inhibiteurs de l'activité du récepteur cannabinoïde 1
HK1213802A1 (zh) 施用 激動劑的方法和組合物
WO2008013838A3 (fr) Dérivés de pyridizinone
IL228017A0 (en) Quinazolinone derivatives donated at position 5 as anti-cancer agents
IL197275A0 (en) Pharmaceutical compositions of clonazepam and methods of use thereof
WO2008066899A3 (fr) Formulations de nanoparticules et procédés de préparation et d'utilisation de celles-ci
IL182527A0 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
IL195030A (en) IV dpp inhibitor assemblies
WO2007120575A3 (fr) Agonistes du récepteur de la niacine, compositions contenant de tels composés et méthodes de traitement
HK1122034A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
WO2007139860A3 (fr) Inhibiteurs hétérobicycliques des métalloprotéases
EP1841761A4 (fr) Derives de fumagillol et methode de preparation de derives de fumagillol et compositions pharmaceutiques comprenant ces derniers
CA2725933A1 (fr) Combinaisons de medicaments comprenant un inhibiteur de dgat et un agoniste de ppar
WO2007095043A3 (fr) Formulations pharmaceutiques
WO2007092364A3 (fr) Agonistes du recepteur de la niacine, compositions contenant de tels composes et procedes de traitement
AU2007306104A1 (en) Hydrobenzamide derivatives as inhibitors of Hsp90
WO2008054808A3 (fr) Compositions pharmaceutiques d'elvucitabine
WO2007056142A3 (fr) Procedes de prevention du syndrome serotoninergique et compositions utilisees a cette fin
WO2008051403A3 (fr) Agonistes de récepteur de niacine, compositions contenant ces composes et procédés de traitement

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07837336

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07837336

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载